US FDA Finalises Psychedelic Trial Guidance and Sets September Public Hearing

The United States Food and Drug Administration (FDA) has finalised its guidance for companies running clinical trials of psychedelic drugs, and announced a public hearing on the “potential future therapeutic use of psychedelic drugs in supervised and supportive settings”, to be held on 14 September 2026.

What was announced

In a Federal Register notice published on 14 July 2026, the FDA said the hearing will gather input on provider training and credentialing standards, patient safety practices, access considerations such as workforce and reimbursement, and data collection methods. The notice names psilocybin — under study for treatment-resistant depression and major depressive disorder — and methylone, under study for post-traumatic stress disorder, among the substances in developers’ pipelines. Public comments are open until 5 October 2026.

The finalised trial guidance updates a draft first issued in 2023, with reporting by Endpoints News indicating the final version eases some abuse-related study requirements for developers. The moves come amid a broader run of US federal activity: Psychedelic Alpha reports a five-year research partnership between the US health department and the Department of Veterans Affairs on psychedelics for veterans’ mental health, and new federal funding streams for ibogaine research.

Why this matters for Australians

Australia and the United States are on different regulatory paths. Australia moved first on access — since July 2023, individually authorised psychiatrists here have been able to prescribe psilocybin for treatment-resistant depression and MDMA for PTSD under the TGA’s Authorised Prescriber scheme — but no psychedelic has yet been approved as a registered medicine in either country. The FDA process matters to Australian readers because a US approval would likely influence which products global sponsors bring to the TGA, the evidence base Australian regulators draw on, and the direction of trial activity worldwide, including trials that recruit in Australia.

For now, the practical position in Australia is unchanged: psilocybin and MDMA remain accessible only through the Authorised Prescriber clinical pathway, and other psychedelics remain prohibited outside approved clinical trials.